Skip to main content

Table 5 Clinical outcome

From: Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses

Groups a

0

1

2

3

4

5

6

Total

 

EcoVag®

Lc4R5

Lc23B33

Lc21M49

Lg14869,

Lg14869

LaciBios®

 
 

Lg 14869

Lg 20M39

Lg 6M9

Lg 6M9

Lr 14870,

Lr 14870

Lr GR-1

 
 

Lr 14870

Lj 22B42

Lj 12B1

Lc 8R6

Lg 15527

Lg 15527

Lr RC-14

 
 

Vaginal

Vaginal

Vaginal

Vaginal

Vaginal

Oral

Oral

 
 

n = 9

n = 12

n = 10

n = 10

n = 9

n = 4

n = 9

n = 63

6-month cure (no. and percentage)

8 (89%)

9 (75%)

8 (80%)

6 (60%)

6 (67%)

2 (50%)

8 (89%)

47 (74.6%)

12-month cure (no. and percentage)

7 (78%)

7 (58%)

6 (60%)

7 (70%)

6 (67%)

2 (50%)

6 (67%)

41 (65.1%)

24-month cure (no. and percentage)

5 (56%)

4 (33%)

6 (60%)

6 (60%)

6 (67%)

2 (50%)

6 (67%)

35 (55.6%)

Number of patients with new relation during follow up (no. and percentage of all)

2 (22%)

4 (33%)

4 (40%)

4 (40%)

2 (22%)

3 (75%)

3 (33%)

22 (34.9%)

  1. a Each group are given capsules with a mix of two or three Lactobacillus strains: Lg, L. gasseri; Lr, L. rhamnosus; Lc, L. crispatus; Lj, L. jenseneii